At Stock Options Channel, our YieldBoost formula has looked up and down the THRX options chain for the new September 18th contracts and identified one put and one call contract of particular interest. The put contract at the …
Investors in Theravance (NASD: THRX) saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the THRX options chain for the new July 19th …
Theravance (THRX): THRX stock is up 2.3% today ... Article printed from InvestorPlace Media, http://investorplace.com/2015/03/hottest-healthcare-stocks-now-rdy-regn-thrx-ziop-rdy-regn-thrx/.
Dr. Reddy's Laboratories
News articles about Innoviva (NASDAQ:THRX) have trended somewhat positive this week, Alpha One Sentiment Analysis reports. Alpha One, a service of Accern, identifies positive and negative press coverage by reviewing more than 20 …
In a report made public by Cowen on Thursday, 29 October, Theravance Biopharma Inc (NASDAQ:THRX) had its PT downgraded to $10.00. The firm presently has Market Perform rating on the stock. After (NASDAQ:THRX) target …
Ortiz and President Scott Matthew Colosi sold 152,896 shares of TXRH stock in February and May. Theravance Inc. (THRX): CEO Rick E. Winningham sold 255,532 Shares CEO of Theravance Inc. (THRX) Rick E. Winningham sold …
With this in mind, let’s take each company one by one, starting with Theravance Inc (NASDAQ:THRX), whose stock
meaning that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the next several days. Get Innoviva Inc alerts: Innoviva (NASDAQ:THRX) remained flat at $9.81 during trading on Thursday. The firm’s 50 …
BNS9d
Theravance Inc. was a big mover last session with its shares rising over 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company, as …
Media headlines about Innoviva (NASDAQ:THRX) have trended positive recently, according to AlphaOne Sentiment Analysis. The research firm, a division of Accern, identifies negative and positive press coverage by analyzing more …